Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Zhengzhou UniversityNo recent work listed

Kai Luo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4567-4039; OpenAlex author ID A5112110139. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper

Papers 3

  1. The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.933645↗
  2. Oxysterol-Binding Protein 2 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Epithelial-Mesenchymal Transition. Co-author DOI 10.3389/fonc.2021.762233↗
  3. Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice. First author DOI 10.5754/hge11271↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuai Huang · 2 shared papers, 2021–2022 · strength 0.34
  2. Renfeng Li · 1 shared paper, 2022 · strength 0.19
  3. Jianhua Jiang · 1 shared paper, 2021 · strength 0.16
  4. Xueping Lin · 1 shared paper, 2012 · strength 0.04
  5. Jian Jun Huang · 1 shared paper, 2012 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.